{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:30:10Z","timestamp":1785814210830,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1208\/s12249-020-01898-4","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T16:10:51Z","timestamp":1609949451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sirolimus-Loaded Intravitreal Implant for Effective Treatment of Experimental Uveitis"],"prefix":"10.1208","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-7904","authenticated-orcid":false,"given":"Mayara Rodrigues Brand\u00e3o De","family":"Paiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V\u00edtor","family":"Vasconcelos-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena Carla","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia Lig\u00f3rio","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Silva-Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"1898_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10238-015-0345-6","volume":"16","author":"M Prete","year":"2016","unstructured":"Prete M, Dammacco R, Fatone MC, Racanelli V. Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. Clin Exp Med. 2016;16:125\u201336. https:\/\/doi.org\/10.1007\/s10238-015-0345-6.","journal-title":"Clin Exp Med"},{"key":"1898_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/ceo.13511","volume":"47","author":"M Hassan","year":"2019","unstructured":"Hassan M, Karkhur S, Bae J, Halim S, Ormaechea MS, Nguyen NV, et al. New therapies in development for the management of non- infectious uveitis: a review. Clin Experiment Ophthalmol. 2019;47:396\u2013417. https:\/\/doi.org\/10.1111\/ceo.13511.","journal-title":"Clin Experiment Ophthalmol"},{"key":"1898_CR3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","volume":"134","author":"JE Thorne","year":"2016","unstructured":"Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, et al. Prevalence of noninfectious uveitis in the United States. JAMA Ophthalmol. 2016;134:1237\u201345. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.3229.","journal-title":"JAMA Ophthalmol"},{"key":"1898_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12348-018-0148-5","volume":"8","author":"MM Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez MM, Solano MM, Porco TC, Oldenburg CE, Acharya NR, Lin SC, et al. Epidemiology of uveitis in a US population-based study. J Ophthalmic Inflamm Infect. 2018;8:6. https:\/\/doi.org\/10.1186\/s12348-018-0148-5.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1898_CR5","first-page":"475","volume":"21","author":"L Gamalero","year":"2019","unstructured":"Gamalero L, Simonini G, Ferrara G, Polizzi S, Giani T, Cimaz R. Evidence-based treatment for uveitis. Isr Med Assoc J. 2019;21:475\u20139.","journal-title":"Isr Med Assoc J"},{"key":"1898_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14728214.2019.1663823","volume":"24","author":"U Pleyer","year":"2019","unstructured":"Pleyer U, Pohlmann D, Karde\u015f E, Poddubnyy D, Rademacher J. Emerging drugs for the treatment of noninfectious uveitis. Expert Opin Emerg Drugs. 2019;24:173\u201390. https:\/\/doi.org\/10.1080\/14728214.2019.1663823.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1898_CR7","doi-asserted-by":"publisher","unstructured":"Knickelbein JE, Armbrust KR, Kim M, Sen HN, Nussenblatt RB. Pharmacologic treatment of noninfectious uveitis. Pharmacol Ther Ocul Dis. 2016:231\u201368. https:\/\/doi.org\/10.1007\/164_2016_21.","DOI":"10.1007\/164_2016_21"},{"key":"1898_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"M Bjornsti","year":"2004","unstructured":"Bjornsti M, Houghton PJ. The tor pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335\u201348. https:\/\/doi.org\/10.1038\/nrc1362.","journal-title":"Nat Rev Cancer"},{"key":"1898_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jconrel.2005.10.008","volume":"110","author":"ML Forrest","year":"2006","unstructured":"Forrest ML, Won CY, Malick AW, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(\u03b5-caprolactone) micelles. J Control Release. 2006;110:370\u20137. https:\/\/doi.org\/10.1016\/j.jconrel.2005.10.008.","journal-title":"J Control Release"},{"key":"1898_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcp.1041540103","volume":"154","author":"N Terada","year":"1993","unstructured":"Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol. 1993;154:7\u201315. https:\/\/doi.org\/10.1002\/jcp.1041540103.","journal-title":"J Cell Physiol"},{"key":"1898_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1208\/s12249-014-0244-2","volume":"16","author":"K Cholkar","year":"2014","unstructured":"Cholkar K, Gunda S, Earla R, Pal D, Mitra AK. Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery. AAPS PharmSciTech. 2014;16:610\u201322 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25425389.","journal-title":"AAPS PharmSciTech"},{"key":"1898_CR12","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","volume":"123","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III sirolimus study assessing double-masKed uveitis TReAtment (SAKURA). Am Acad Ophthalmol. 2016;123:2413\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.029.","journal-title":"Am Acad Ophthalmol"},{"key":"1898_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1517\/14656566.2016.1124855","volume":"17","author":"U Pleyer","year":"2016","unstructured":"Pleyer U, Thurau SR. Sirolimus for the treatment of noninfectious uveitis. Expert Opin Pharmacother. 2016;17:127\u201335 http:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-84955500539&partnerID=tZOtx3y1.","journal-title":"Expert Opin Pharmacother"},{"key":"1898_CR14","doi-asserted-by":"publisher","unstructured":"Nguyen QD, Merrill PT, Sepah YJ, Ibrahim MA, Banker A, Leonardi A, et al. Intravitreal sirolimus for the treatment of noninfectious uveitis evolution through preclinical and clinical studies 2018;125:1984\u20131993. https:\/\/doi.org\/10.1016\/j.ophtha.2018.06.015.","DOI":"10.1016\/j.ophtha.2018.06.015"},{"key":"1898_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","volume":"126","author":"A Mandal","year":"2018","unstructured":"Mandal A, Pal D, Agrahari V, Trinh HM, Joseph M, Mitra AK. Ocular delivery of proteins and peptides: challenges and novel formulation approaches. Adv Drug Deliv Rev. 2018;126:67\u201395. https:\/\/doi.org\/10.1016\/j.addr.2018.01.008.","journal-title":"Adv Drug Deliv Rev"},{"key":"1898_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.drudis.2019.03.018","volume":"24","author":"R Neumann","year":"2019","unstructured":"Neumann R, Barequet D. The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies. Drug Discov Today. 2019;24:1433\u20135. https:\/\/doi.org\/10.1016\/j.drudis.2019.03.018.","journal-title":"Drug Discov Today"},{"key":"1898_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/02713683.2013.819927","volume":"39","author":"MCM Souza","year":"2014","unstructured":"Souza MCM, Fialho SL, Souza PAF, Fulg\u00eancio GO, Da Silva GR, Silva-Cunha A. Tacrolimus-loaded PLGA implants: In vivo release and ocular toxicity. Curr Eye Res. 2014;39:99\u2013102. https:\/\/doi.org\/10.3109\/02713683.2013.819927.","journal-title":"Curr Eye Res"},{"key":"1898_CR18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1208\/s12249-013-9977-6","volume":"14","author":"AGR Solano","year":"2013","unstructured":"Solano AGR, De F\u00e1tima PA, Pinto FCH, Ferreira LGR, De Oliveira Barbosa LA, Fialho SL, et al. Development and evaluation of sustained-release etoposide-loaded poly(\u03b5-caprolactone) implants. AAPS PharmSciTech. 2013;14:890\u2013900. https:\/\/doi.org\/10.1208\/s12249-013-9977-6.","journal-title":"AAPS PharmSciTech"},{"key":"1898_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-018-9664-8","volume":"138","author":"MRB de Paiva","year":"2018","unstructured":"de Paiva MRB, Lage NA, Guerra MCA, Mol MPG, Ribeiro MCS, Fulg\u00eancio GDO, et al. Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits\u2019 eyes. Doc Ophthalmol. 2018;138:1\u201317. https:\/\/doi.org\/10.1007\/s10633-018-9664-8.","journal-title":"Doc Ophthalmol"},{"key":"1898_CR20","doi-asserted-by":"publisher","first-page":"106129","DOI":"10.1016\/j.intimp.2019.106129","volume":"81","author":"BFM Castro","year":"2020","unstructured":"Castro BFM, Vieira LC, Vasconcelos-Santos DV, Cenachi SP d F, Cotta OAL, Guerra MCA, et al. Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. Int Immunopharmacol. 2020;81:106129. https:\/\/doi.org\/10.1016\/j.intimp.2019.106129.","journal-title":"Int Immunopharmacol"},{"key":"1898_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"The standardization of uveitis nomenclature (SUN) working group","year":"2005","unstructured":"The standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u201316. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057.","journal-title":"Am J Ophthalmol"},{"key":"1898_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265\u201375.","journal-title":"J Biol Chem"},{"key":"1898_CR23","doi-asserted-by":"publisher","first-page":"118466","DOI":"10.1016\/j.ijpharm.2019.118466","volume":"568","author":"RO Silva","year":"2019","unstructured":"Silva RO, da Costa BL, da Silva FR, da Silva CN, de Paiva MB, Dourado LFN, et al. Treatment for chemical burning using liquid crystalline nanoparticles as an ophthalmic delivery system for pirfenidone. Int J Pharm. 2019;568:118466. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118466.","journal-title":"Int J Pharm"},{"key":"1898_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.biopha.2012.08.006","volume":"67","author":"BG Pereira","year":"2013","unstructured":"Pereira BG, Ligorio Fialho S, Maria de Souza C, Dantas Cassali G, Silva-Cunha A. Evaluation of the effects of thalidomide-loaded biodegradable devices in solid Ehrlich tumor. Biomed Pharmacother. 2013;67:129\u201332. https:\/\/doi.org\/10.1016\/j.biopha.2012.08.006.","journal-title":"Biomed Pharmacother"},{"key":"1898_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/02713680490904368","volume":"30","author":"T Ishikawa","year":"2005","unstructured":"Ishikawa T, Hokama H. Effects of Intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr Eye Res. 2005;30:93\u2013101. https:\/\/doi.org\/10.1080\/02713680490904368.","journal-title":"Curr Eye Res"},{"key":"1898_CR26","first-page":"442","volume":"36","author":"C Cheng","year":"1995","unstructured":"Cheng C, Berger AS, Pearson PA, Ashton P, Jaffe GJ. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36:442\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1898_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jop.2017.0053","volume":"33","author":"K Papangkorn","year":"2017","unstructured":"Papangkorn K, Prendergast E, Higuchi JW, Brar B, Higuchi WI. Noninvasive ocular drug delivery system of dexamethasone sodium phosphate in the treatment of experimental uveitis rabbit. J Ocul Pharmacol Ther. 2017;33:1\u201310. https:\/\/doi.org\/10.1089\/jop.2017.0053.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1898_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0161-6420(98)91176-9","volume":"105","author":"GJ Jaffe","year":"1998","unstructured":"Jaffe GJ, Yang C, Wang IX, Cousins ISW, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46\u201356. https:\/\/doi.org\/10.1016\/S0161-6420(98)91176-9.","journal-title":"Ophthalmology."},{"key":"1898_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10792-013-9829-0","volume":"34","author":"W Li","year":"2014","unstructured":"Li W, He B, Dai W, Zhang Q, Liu Y. Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis. Int Ophthalmol. 2014;34:465\u201376. https:\/\/doi.org\/10.1007\/s10792-013-9829-0.","journal-title":"Int Ophthalmol"},{"key":"1898_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.30466\/vrf.2018.32083","volume":"9","author":"MR Khalili","year":"2018","unstructured":"Khalili MR, Amini AH, Hasiri MA, Moghaddam EB, Eghtedari M, Azizzadeh M, et al. Evaluation of intravitreal injection of pentoxifylline in experimental endotoxin-induced uveitis in rabbits. Vet Res Forum. 2018;9:239\u201344. https:\/\/doi.org\/10.30466\/vrf.2018.32083.","journal-title":"Vet Res Forum"},{"key":"1898_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10837450.2019.1578370","volume":"24","author":"M Alami-milani","year":"2019","unstructured":"Alami-milani M, Zakeri-milani P, Valizadeh H, Sattari S, Salatin S, Jelvehgari M. Evaluation of anti-inflammatory impact of dexamethasone-loaded PCL-PEG-PCL micelles on endotoxin-induced uveitis in rabbits. Pharm Dev Technol. 2019;24:1\u20139. https:\/\/doi.org\/10.1080\/10837450.2019.1578370.","journal-title":"Pharm Dev Technol"},{"key":"1898_CR32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/archopht.1980.01020031100019","volume":"98","author":"GA Bolliger","year":"1980","unstructured":"Bolliger GA, Kupferman A, Leibowitz HM. Quantitation of anterior chamber inflammation and its therapy. Arch Ophthalmol. 1980;98:1110\u20134. https:\/\/doi.org\/10.1001\/archopht.1980.01020031100019.","journal-title":"Arch Ophthalmol"},{"key":"1898_CR33","doi-asserted-by":"publisher","first-page":"1700733","DOI":"10.1002\/adhm.201700733","volume":"6","author":"ML Ratay","year":"2017","unstructured":"Ratay ML, Bellotti E, Gottardi R, Little SR. Modern therapeutic approaches for noninfectious ocular diseases involving inflammation. Adv Healthc Mater. 2017;6:1700733. https:\/\/doi.org\/10.1002\/adhm.201700733.","journal-title":"Adv Healthc Mater"},{"key":"1898_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2147\/IJN.S179118","volume":"14","author":"X Yu","year":"2019","unstructured":"Yu X, Zhang R, Lei L, Song Q, Li X. High drug payload nanoparticles formed from dexamethasone-peptide conjugates for the treatment of endotoxin-induced uveitis in rabbit. Int J Nanomedicine. 2019;14:591\u2013603. https:\/\/doi.org\/10.2147\/IJN.S179118.","journal-title":"Int J Nanomedicine"},{"key":"1898_CR35","first-page":"1361","volume":"36","author":"DC Metrikin","year":"1995","unstructured":"Metrikin DC, Wilson CA, Berkowitz BA, Lam XMK, Wood GK, Peshockf RM. Measurement of blood-retinal barrier breakdown in endotoxin-induced Endophthalmitis. Invest Ophthalmol Vis Sci. 1995;36:1361\u201370.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1898_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/15569527.2019.1632883","volume":"38","author":"O Donmez","year":"2019","unstructured":"Donmez O, Yaman A, Ozturk T, Aktas S, Altun ZS, Y\u0131lmaz O. The efficacy of systemic and intravitreal infliximab treatments in an endotoxin-induced uveitis model. Cutan Ocul Toxicol. 2019;38:360\u20139. https:\/\/doi.org\/10.1080\/15569527.2019.1632883.","journal-title":"Cutan Ocul Toxicol"},{"key":"1898_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1167\/iovs.01-1202","volume":"44","author":"H Xu","year":"2003","unstructured":"Xu H, Forrester JV, Liversidge J, Crane IJ. Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Investig Ophthalmol Vis Sci. 2003;44:226\u201334. https:\/\/doi.org\/10.1167\/iovs.01-1202.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1898_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-020-1333-5","volume":"20","author":"DA Lipski","year":"2020","unstructured":"Lipski DA, Foucart V, Dewispelaere R, Caspers LE, Defrance M, Bruyns C, et al. Retinal endothelial cell phenotypic modifications during experimental autoimmune uveitis: a transcriptomic approach. BMC Ophthalmol BMC Ophthalmology. 2020;20:1\u201325. https:\/\/doi.org\/10.1186\/s12886-020-1333-5.","journal-title":"BMC Ophthalmol BMC Ophthalmology"},{"key":"1898_CR39","doi-asserted-by":"publisher","unstructured":"M\u00e9rida S, Palacios E, Navea A, Bosch-morell F. Macrophages and uveitis in experimental animal models. Mediat Inflamm. 2015. https:\/\/doi.org\/10.1155\/2015\/671417.","DOI":"10.1155\/2015\/671417"},{"key":"1898_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s1056-8719(98)00023-9","volume":"39","author":"G Graff","year":"1998","unstructured":"Graff G, Gamache DA, Brady MT, Spellman JM, Yanni JM. Improved myeloperoxidase assay for quantitation of neutrophil influx in a rat model of endotoxin-induced uveitis. J Pharmacol Toxicol Methods. 1998;39:169\u201378. https:\/\/doi.org\/10.1016\/s1056-8719(98)00023-9.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1898_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1089\/jop.2008.0134","volume":"25","author":"J Karim","year":"2009","unstructured":"Karim J, Bhattacherjee P, Biswas S, Paterson CA, Al KET. Anti-inflammatory effects of lipoxins on lipopolysaccharide-induced uveitis in rats. J Ocul Pharmacol Ther. 2009;25:483\u20136. https:\/\/doi.org\/10.1089\/jop.2008.0134.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1898_CR42","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/14740338.2019.1692810","volume":"18","author":"MS Ormaechea","year":"2019","unstructured":"Ormaechea MS, Hassan M, Onghanseng N, Park H, Mahajan S, Al-kirwi KY, et al. Expert opinion on drug safety safety of systemic therapy for noninfectious uveitis. Expert Opin Drug Saf. 2019;18:1219\u201335. https:\/\/doi.org\/10.1080\/14740338.2019.1692810.","journal-title":"Expert Opin Drug Saf"},{"key":"1898_CR43","doi-asserted-by":"publisher","unstructured":"Testi I, Pavesio C. Preliminary evaluation of YUTIQ \u2122 ( fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. 2019;10:621\u20135. https:\/\/doi.org\/10.4155\/tde-2019-0051","DOI":"10.4155\/tde-2019-0051"},{"key":"1898_CR44","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40265-020-01314-y","volume":"80","author":"LM Valdes","year":"2020","unstructured":"Valdes LM, Sobrin L. Uveitis therapy : the corticosteroid options. Drugs. 2020;80:765\u201373. https:\/\/doi.org\/10.1007\/s40265-020-01314-y.","journal-title":"Drugs"},{"key":"1898_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.4.2.4","volume":"4","author":"MA Ibrahim","year":"2015","unstructured":"Ibrahim MA, Sepah YJ, Watters A, Bittencourt M, Vigil EM, Do DV, et al. One-year outcomes of the SAVE study: sirolimus as a therapeutic approach for UVEitis. Transl Vis Sci Technol. 2015;4:4 http:\/\/tvst.arvojournals.org\/Article.aspx?doi=10.1167\/tvst.4.2.4.","journal-title":"Transl Vis Sci Technol"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-020-01898-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T06:53:20Z","timestamp":1611903200000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-020-01898-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1208\/s12249-020-01898-4","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"17 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}